- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Elutia Inc.: Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1 | 1 | GlobeNewswire (USA) | ||
| 11.03. | ELUTIA INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 08.03. | Elutia Inc reports results for the quarter ended in December - Earnings Summary | 2 | Reuters | ||
| 07.03. | Recap: Elutia Q4 Earnings | 2 | Benzinga.com | ||
| 07.03. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.03. | Elutia Inc.: Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM Clearance Decision in First Half of 2024 | 166 | GlobeNewswire (Europe) | SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company") today provided a business update and reported financial results for the fourth quarter... ► Artikel lesen | |
| 06.03. | Preview: Elutia's Earnings | 1 | Benzinga.com | ||
| 22.02. | Elutia Inc.: Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024 | 2 | GlobeNewswire (USA) | ||
| 02.02. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.01. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 10.01. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.01. | Elutia regains compliance with Nasdaq | 1 | Seeking Alpha | ||
| 10.01. | Elutia Inc.: Elutia Regains Compliance with Nasdaq Listing Requirements | 196 | GlobeNewswire (Europe) | SILVER SPRING, Md., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) today announced that it has regained compliance with Nasdaq's market value of listed securities requirement and majority... ► Artikel lesen | |
| 27.12.23 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.12.23 | Elutia submits drug-eluting biomatrix for use with cardiac implants to FDA | 2 | MassDevice | ||
| 08.12.23 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.11.23 | Elutia files to sell 18.58M shares of Class A common stock for holders | 1 | Seeking Alpha | ||
| 20.11.23 | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.11.23 | ELUTIA INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 14.11.23 | Where Elutia Stands With Analysts | 1 | Benzinga.com |
Seite:
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,610 | -1,53 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,938 | -5,82 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,973 | -1,53 % | GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener | Plant Trait Services, Protein Services, and Deployment Capabilities JONESBORO, Ark. and BOSTON, May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing... ► Artikel lesen | |
| BEAM THERAPEUTICS | 22,565 | -0,94 % | Beam Therapeutics Inc. - 10-Q, Quarterly Report | ||
| RECURSION PHARMACEUTICALS | 8,630 | -3,47 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
| ONCOLYTICS BIOTECH | 1,090 | -0,91 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ASSERTIO | 1,095 | -10,25 % | Assertio Holdings, Inc.: Assertio Reports First Quarter 2024 Financial Results | First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 27,200 | -0,44 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 10,420 | +0,29 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,050 | +0,23 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 9,920 | -2,98 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,155 | -4,13 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,380 | -0,74 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,920 | +7,75 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| ARVINAS | 34,340 | +6,45 % | Arvinas Inc.: Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update | - Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study... ► Artikel lesen |
ELUTIA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +1,74 % bei einem Aktienkurs von 2,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
